Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024
Here's What Analysts Are Forecasting For Royalty Pharma Plc (NASDAQ:RPRX) After Its First-Quarter Results
Only Four Days Left To Cash In On Royalty Pharma's (NASDAQ:RPRX) Dividend
Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading
Health care stocks were rising Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.8%. The iShares Biotechnology ETF (IBB) rose 0.7%. In
Royalty Pharma | 10-Q: Quarterly report
Royalty Pharma's Q1 Net Income, Revenue Falls
Royalty Pharma (RPRX) reported Thursday Q1 net income attributable to the company of $5 million, down from $341 million a year earlier. Analysts' estimates were not readily available for comparison. T
Royalty Pharma To Acquire Royalties And Milestones On Frexalimab Owned By ImmuNext For ~$525M In Cash Including Estimated Transaction Costs
Under the terms of ImmuNext's licensing agreement with Sanofi, ImmuNext is entitled to receive an upward tiering net royalty ranging from a high-single digit to low-double digit percentage of worldwid
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q1 Revenue $568M, Vs. Street Est of $709.5M
07:17 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (RPRX) ROYALTY PHARMA Reports Q1 Revenue $568M, vs. Street Est of $709.5M
Royalty Pharma (RPRX.US): The 2024 Q1 financial report achieved revenue of US$568 million, with a previous value of US$684 million, with an expected value of US$663.2 million; earnings per share were US$0.98, the previous value was US$1.60, and the expect
Royalty Pharma (RPRX.US): The 2024 Q1 financial report achieved revenue of US$568 million, with a previous value of US$684 million, with an expected value of US$663.2 million; earnings per share were US$0.98, the previous value was US$1.60, and the expected value was US$0.99.
Royalty Pharma Q1 Sales $568.00M Miss $663.22M Estimate
Royalty Pharma (NASDAQ:RPRX) reported quarterly sales of $568.00 million which missed the analyst consensus estimate of $663.22 million by 14.36 percent. This is a 16.96 percent decrease over sales o
Royalty Pharma 1Q Net $5M >RPRX
Royalty Pharma 1Q Net $5M >RPRX
Press Release: Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab
Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab -- Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of
Teva Hits a Five-year High on Schizophrenia Trial Win, Q1 Beat
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be $0.21
Arrowhead Nets $50 Milestone Payment From Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug
Arrowhead Pharmaceuticals (ARWR) said Thursday it received a $50 million milestone payment from Royalty Pharma (RPRX) after completion of the enrollment of a phase 3 trial of olpasiran, a potential ca
Amgen Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results. Also, the Company Announced a $50 Million Milestone Payment From Royalty Pharma.
Amgen Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results. Also, the Company Announced a $50 Million Milestone Payment From Royalty Pharma.
Arrowhead Pharmaceuticals Secures $50M Milestone From Royalty Pharma
What Royalty Pharma Plc's (NASDAQ:RPRX) P/S Is Not Telling You
You may think that with a price-to-sales (or "P/S") ratio of 5.3x Royalty Pharma plc (NASDAQ:RPRX) is a stock to avoid completely, seeing as almost half of all the Pharmaceuticals companies in the Uni
No Data